Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 15/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1329756 | 0.83 | PTGDR2 (0.46) | MET | |
| SCHEMBL3593816 | 0.82 | MET (0.42) | METHTT | |
| SCHEMBL1163294 | 0.82 | MET (0.44) | METHTT | |
| Propionic Acid SCHEMBL27899901 | 0.82 | PTGDR2 (0.45) | MET | |
| SCHEMBL10162620 | 0.80 | MET (0.43) | MET | |
| SCHEMBL27875686 | 0.79 | MET (0.45) | MET | |
| SCHEMBL1330431 | 0.78 | MET (0.43) | MET | |
| SCHEMBL3162427 | 0.78 | MAPK8 (0.41) | METALOX15HTT | |
| SCHEMBL3149520 | 0.78 | TSHR (0.36) | METEGFRHTT | |
| SCHEMBL3158179 | 0.78 | MET (0.40) | METEGFRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2673277-A1 | [1, 2, 4]TRIAZOLO [4, 3 -B]PYRIDAZINE COMPOUNDS AS INHIBITORS OF THE C-MET TYROSINE KINASE | Novartis AG (CH) | 2013-12-18 | — | — | EP | disclosed |
| CN-103459396-A | [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of c-met tyrosine kinase | NOVARTIS AG | 2013-12-18 | — | — | CN | disclosed |
| US-20130324526-A1 | [1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE COMPOUNDS AS INHIBITORS OF THE C-MET TYROSINE KINASE | NOVARTIS AG (CH) | 2013-12-05 | — | — | US | disclosed |
| US-8507676-B2 | Heterocyclic oxime compounds | NOVARTIS AG (CH) | 2013-08-13 | — | — | US | disclosed |
| US-8507676-B2 | Heterocyclic oxime compounds | NOVARTIS AG (CH) | 2013-08-13 | — | — | US | disclosed |
| US-8507676-B2 | Heterocyclic oxime compounds | NOVARTIS AG (CH) | 2013-08-13 | — | — | US | disclosed |
| US-8497368-B2 | Heterocyclic hydrazone compounds | NOVARTIS AG (CH) | 2013-07-30 | — | — | US | disclosed |
| US-8497368-B2 | Heterocyclic hydrazone compounds | NOVARTIS AG (CH) | 2013-07-30 | — | — | US | disclosed |
| US-8497368-B2 | Heterocyclic hydrazone compounds | NOVARTIS AG (CH) | 2013-07-30 | — | — | US | disclosed |
| US-8410264-B2 | Heterocyclic oxime compounds | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| WO-2011020861-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2011-02-24 | — | — | WO | disclosed |
| WO-2011020861-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2011-02-24 | — | — | WO | disclosed |
| WO-2011018454-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS AND THEIR USES TO TREAT CANCER AND INFLAMMATION | NOVARTIS AG (CH) | 2011-02-17 | — | — | WO | disclosed |
| WO-2011018454-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS AND THEIR USES TO TREAT CANCER AND INFLAMMATION | NOVARTIS AG (CH) | 2011-02-17 | — | — | WO | disclosed |
| US-20100120739-A1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
| EP-2162132-A1 | HETEROCYCLIC KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| EP-2081937-A2 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20090156594-A1 | HETEROCYCLIC KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2008144767-A1 | HETEROCYCLIC KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008051805-A2 | TRIAZOLO-PYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324526-A1 | [1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE COMPOUNDS AS INHIBITORS OF THE C-MET TYROSINE KINASE | MET, ERBB2, RET | MET 1/4885EGFR 27/4885ALOX15 3758/4885 |
| US-20090156594-A1 | HETEROCYCLIC KINASE MODULATORS | MAP3K20, MAP4K2, MAP3K13 | MET 721/4885EGFR 667/4885ALOX15 4211/4885 |
| US-20100120739-A1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | MAP4K5, MAPKAPK5, MAP4K2 | MET 1025/4885EGFR 1566/4885ALOX15 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.